Biotech Investor Realism with Andrew Fein
Expert healthcare company watcher Andrew Fein of H.C. Wainwright & Co. knows how the sausage is made in the stock analyst factory.
doesn't pull any punches: In this interview with The Life Sciences Report, Fein dishes out praise for sticking to sellside fundamentals and suggests skimming off bloggers who have yet to earn their analytical chops.
rounds out the menu by naming biotech companies with the potential to rise to the top of the simmering biotech market.
Companies Mentioned: CEL-SCI Corp.
: CytRx Corp.
: Kamada Ltd.
: NeoStem Inc.
: Orexigen Therapeutics Inc.
: Synthetic Biologics Inc.
: United Therapeutics Corp.
: Vertex Pharmaceuticals Inc.
The Life Sciences Report: How has the nature of biotech investing changed since you began analyzing healthcare biotech equities in 2000?
: Clearly, the web as a source of "investment analytics" is a new paradigm.
In May 2013, Andrew Fein joined H.C. Wainwright & Co. as managing director and senior biotechnology analyst to cover companies in the biotechnology and life sciences sectors.
He has 13 years of experience in healthcare and biotechnology equity research.
3) Andrew Fein
: I own, or my family owns, shares of the following companies mentioned in this interview: None.